Results 111 to 120 of about 22,324 (258)

Detection of Anti-Infliximab and Anti-Adalimumab Antibodies Below Manufacture's Threshold in a TDM Cohort Using Signal-to-Noise Ratio. [PDF]

Basic Clin Pharmacol Toxicol
Pedersen L.
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 702-712, September 2026.
Busulfan's narrow therapeutic index and high pharmacokinetic (PK) variability warrant investigation of its exposure–toxicity relationship. We retrospectively analyzed 334 pediatric and young adult patients who underwent allogeneic hematopoietic stem cell transplantation at Seoul National University Children's Hospital between 2009 and 2020 and received
Sungyeun Bae, Jung Yoon Choi, Kyung Taek Hong, Bo Kyung Kim, Hyun Jin Park, Kyung‐Sang Yu, Su‐jin Rhee, Hyoung Jin Kang   +7 more
wiley   +1 more source

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. [PDF]

Clin Pharmacokinet
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, Laguna JC, Gorria T, Montes A, Macías I, Alvárez A, Arance A, Moreno FA, Fabregat-Bolufer AB, Soler E, Muner DS.   +15 more
europepmc   +1 more source

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 753-761, September 2026.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Influence of arrogance on acceptance of TDM policy

Journal of Human Environmental Studies, 2012
Junghwa Kim, Jan-Dirk Schmocker, Satoshi Fujii   +2 more
doaj   +1 more source

Early Experience With Beta-Lactam Therapeutic Drug Monitoring in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program. [PDF]

Open Forum Infect Dis
Barrett KO, Rivera CG, Abu Saleh O, Pertzborn M, Ausman SE, Rule AD, Arensman Hannan K, Stevens RW, Barreto EF.   +8 more
europepmc   +1 more source

Pitfalls in TDM

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015
Kazuaki Taguchi, Junji Saruwatari, Kenshiro Hirata, Toru Maruyama   +3 more
openaire   +2 more sources

Defining a Therapeutic Window for Venetoclax in Post‐Transplant Maintenance Therapy for High‐Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Patients with high‐risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) continue to face a substantial risk of relapse after allogeneic hematopoietic stem cell transplantation (allo‐HSCT), which remains a leading cause of treatment failure.
Cuicui Lyu, Tianle Xie, Yedi Pu, Xianshuang Luan, Xia Xiao, Mingfeng Zhao, Hairong Lyu   +6 more
wiley   +1 more source

Clinical Impact of Linezolid Therapeutic Drug Monitoring on the Tolerability of Prolonged Courses in the Outpatient Setting. [PDF]

Open Forum Infect Dis
Harrington JM, Nagel JL, Sallerson S, Yan X, Aitken SL, Marshall VD, Lawless B, Pai MP, Pogue JM, Eschenauer G.   +9 more
europepmc   +1 more source

Population Pharmacokinetics and Dose De‐Escalation Regimens of Subcutaneous Vedolizumab in Inflammatory Bowel Disease

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background Vedolizumab is a therapeutic antibody approved for the treatment of Crohn's disease and ulcerative colitis. The population pharmacokinetics (popPK) of intravenous (IV) administered vedolizumab have been described, but remain to be defined for subcutaneous (SC) administration.
S. I. Anjie, N. Vreman, K. B. Gecse, M. Löwenberg, G. R. D'Haens, R. A. A. Mathôt   +5 more
wiley   +1 more source